Graviton, Author at Sagimet Biosciences

Sagimet Biosciences Announces Late-Breaking, Oral and Poster Presentations for Denifanstat (TVB-2640), a First-in-Class Fatty Acid Synthase Inhibitor, in NASH at AASLD’s The Liver Meeting

By Graviton / 10/2022

Additional Preclinical Data on Denifanstat Published in Scientific Reports San Mateo, California, October 31, 2022 – Sagimet Biosciences, a clinical-stage biopharmaceutical […]

PRESS RELEASES

Sagimet Biosciences Announces Appointment of David Happel to Chief Executive Officer; Dr. George Kemble to Transition to Executive Chairman Role

By Graviton / 10/2022

San Mateo, California, October 24, 2022 – Sagimet Biosciences, a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic pathways,

NASH

FASN inhibition targets multiple drivers of NASH by reducing steatosis, inflammation and fibrosis in preclinical models

By Graviton / 09/2022

Scientific Reports

PRESS RELEASES

Sagimet Biosciences Announces Completion of Patient Enrollment in Phase 2b ‘FASCINATE-2’ Clinical Trial with Denifanstat (TVB-2640), a First-in-Class Fatty Acid Synthase Inhibitor, in Non-alcoholic Steatohepatitis

By Graviton / 09/2022

San Mateo, California, September 13, 2022 – Sagimet Biosciences, a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic pathways, announced

PRESS RELEASES

Sagimet Biosciences Announces Oral Presentation on Denifanstat at Keystone Symposia in Nonalcoholic Steatohepatitis (NASH)

By Graviton / 08/2022

San Mateo, California, August 4, 2022 – Sagimet Biosciences, a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic pathways, announced

Oncology

Targeting de novo lipogenesis and the Lands cycle induces ferroptosis in KRAS-mutant lung cancer

By Graviton / 07/2022

Nature Communications

NASH

A baseline signature of metabolites involving the gut-liver axis predicts MRI-PDFF response to FASN inhibitor TVB-2640 in NASH patients: results from the FASCINATE-1 study

By Graviton / 06/2022

EASL International Liver Congress

PRESS RELEASES

Sagimet Biosciences Announces Presentation of Additional Phase 2 Data on Denifanstat Identifying a Predictive Metabolic Signature in NASH Patients at EASL’s International Liver Congress (ILC) 2022

By Graviton / 06/2022

San Mateo, California, June 8, 2022 – Sagimet Biosciences, a clinical-stage biotechnology company focused on developing a portfolio of internally discovered,

NASH, PUBLICATIONS

Novel, first-in-class, fatty acid synthase (FASN) inhibitor TVB-2640: efficacy, safety and biomarker results from a global phase 2 randomized pbo-controlled NASH trial, FASCINATE-1

By Graviton / 05/2022

Digestive Disease Week

PRESS RELEASES

Sagimet Biosciences to Present Additional Biomarker Phase 2 Data on Denifanstat (TVB-2640) in NASH Patients at DDW 2022

By Graviton / 05/2022

Company Adopts Denifanstat as Non-Proprietary Name for TVB-2640 San Mateo, California, May 4, 2022 – Sagimet Biosciences, a clinical-stage biotechnology company

Author name: Graviton

Sagimet Biosciences Announces Late-Breaking, Oral and Poster Presentations for Denifanstat (TVB-2640), a First-in-Class Fatty Acid Synthase Inhibitor, in NASH at AASLD’s The Liver Meeting

Sagimet Biosciences Announces Appointment of David Happel to Chief Executive Officer; Dr. George Kemble to Transition to Executive Chairman Role

FASN inhibition targets multiple drivers of NASH by reducing steatosis, inflammation and fibrosis in preclinical models

Sagimet Biosciences Announces Completion of Patient Enrollment in Phase 2b ‘FASCINATE-2’ Clinical Trial with Denifanstat (TVB-2640), a First-in-Class Fatty Acid Synthase Inhibitor, in Non-alcoholic Steatohepatitis

Sagimet Biosciences Announces Oral Presentation on Denifanstat at Keystone Symposia in Nonalcoholic Steatohepatitis (NASH)

Targeting de novo lipogenesis and the Lands cycle induces ferroptosis in KRAS-mutant lung cancer

A baseline signature of metabolites involving the gut-liver axis predicts MRI-PDFF response to FASN inhibitor TVB-2640 in NASH patients: results from the FASCINATE-1 study

Sagimet Biosciences Announces Presentation of Additional Phase 2 Data on Denifanstat Identifying a Predictive Metabolic Signature in NASH Patients at EASL’s International Liver Congress (ILC) 2022

Novel, first-in-class, fatty acid synthase (FASN) inhibitor TVB-2640: efficacy, safety and biomarker results from a global phase 2 randomized pbo-controlled NASH trial, FASCINATE-1

Sagimet Biosciences to Present Additional Biomarker Phase 2 Data on Denifanstat (TVB-2640) in NASH Patients at DDW 2022

Site map

Contact us